BITS Pilani
Pilani | Dubai | Goa | Hyderabad | Mumbai
An Institution of Eminence

विज्ञान एवं प्रौद्योगिकी विभाग
DEPARTMENT OF
SCIENCE & TECHNOLOGY
सत्यमेव जयते

BITS Pilani
TECHNOLOGY
ENABLING
CENTRE
DST Supported

PENDING

(IN202311054774)

A pancreatic lipase inhibitor comprising indolyl oxoacetamide-quinazolinone analogues, and a method of preparing the same



NEED

Obesity is a global health issue affecting millions, with limited effective treatment options. Existing treatments often fail to target underlying metabolic factors, leading to inefficiency and side effects.

MARKET ANALYSIS

The global obesity drugs market is projected to grow at a CAGR of 7.6%, reaching $30 billion by 2033 (source: Global Data, 2023). Rising obesity rates and demand for effective treatments drive market growth.

TECHNOLOGY OVERVIEW

This invention provides a novel pancreatic lipase inhibitor, specifically targeting obesity. The compound, based on indolyl oxoacetamide-quinazolinone analogues, blocks pancreatic lipase activity, reducing fat absorption. The technology offers an alternative to existing obesity treatments.

Target Industries

Pharmaceuticals, biotechnology, health & wellness. , Pharmaceutical manufacturers, drug development companies, biotechnology firms focusing on obesity treatment, health and wellness providers, R&D institutions in metabolic diseases.

TECHNOLOGY KEY FEATURES

Novel pancreatic lipase inhibition, targeted obesity treatment, improved fat absorption control, reduced side effects, potential for pharmaceutical applications, scalable production.

AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure), SDG 12 (Responsible Consumption and Production)

Read more here

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,
BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913

innovate achieve lead